Medical treatment of idiopathic heavy menstrual bleeding. What is new? An evidence based approach

In: Archives of Gynecology and Obstetrics · 2012 · vol. 287(2) , pp. 251–260 · doi:10.1007/s00404-012-2605-y · PMID:23117248 · W2085092953
review OA: closed CC0 ⤵ 2 in-corpus citations
AI-generated summary by claude@2026-06+body, 2026-06-07

This review examines current and new medical treatments for idiopathic heavy menstrual bleeding, identifying the levonorgestrel-releasing IUD as most effective and noting emerging evidence for modified-release tranexamic acid, new contraceptive pills, and a contraceptive ring.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text

This evidence-based review examined current and newly introduced medical treatments for idiopathic heavy menstrual bleeding in reproductive-age women, synthesizing results from trials, reviews, and guidelines identified via PubMed to support a practical treatment algorithm. The review found that the levonorgestrel-releasing intrauterine system was the most effective long-term medical therapy, while emerging options with growing evidence included modified-release tranexamic acid, a new four-phasic estradiol valerate/dienogest contraceptive pill, and a contraceptive vaginal ring, along with limited experience using vaginal danazol. The key caveat explicitly noted is that treatment selection is framed for idiopathic heavy menstrual bleeding, implying that evidence may not directly apply to heavy bleeding from specific causes beyond the idiopathic category. Relevance to endometriosis: abnormal uterine bleeding is part of the broader differential evaluated in endometrial-pathology contexts discussed in adjacent cited material, though this paper’s main focus is medical management of idiopathic heavy menstrual bleeding rather than endometriosis itself.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 16,392 characters · extracted from oa-doi-fallback · 5 sections · click to expand

Abstract

Background Heavy menstrual bleeding (HMB) is an important health problem affecting up to 30 % of reproductive age women, interfering with their quality of life. Medical therapy, with the avoidance of unnecessary surgery, is an attractive option. Purpose To provide a comprehensive review of the current medical treatments available for idiopathic HMB and to focus on the newly introduced modalities. Furthermore, to provide a practical algorithm based on the best available evidence.

Methods

A PubMed search was conducted looking for the different trials, reviews and various guidelines relating to medical treatment of idiopathic HMB.

Results

The most effective medical treatment for idiopathic HMB is the levonorgestrel-releasing intrauterine system. It provides a reliable long-term effect. Importantly, there is a growing scientific evidence for new modalities entailing; modified-release formulation of tranexamic acid, the new four-phasic estradiol valerate/dienogest contraceptive pills and combined contraceptive vaginal ring. Also, vaginal danazol has been tried.

Conclusion

Maintenance of status quo, i.e., keeping first-line treatment of idiopathic HMB as medical treatment is an essential issue. Modified-release formulation of tranexamic acid, the new four-phasic contraceptive pills and contraceptive vaginal ring are recently added to the medical armamentarium for treatment of idiopathic HMB increasing its efficacy. Similar content being viewed by others

References

Hallberg L, Högdahl AM, Nilsson L, Rybo G (1966) Menstrual blood loss-a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 45:320–351. doi:10.3109/00016346609158455 Fraser IS, Critchley HO, Broder M, Munro MG (2011) The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med 29:383–390. doi:10.1055/s-0031-1287662 Munro MG, Critchley HO, Fraser IS (2012) The FIGO systems for nomenclature and classification of causes of abnormal uterine bleeding in the reproductive years: who needs them? Am J Obstet Gynecol. doi:10.1016/j.ajog.2012.01.046 Fraser IS, Critchley HO, Munro MG, Broder M (2007) Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? Hum Reprod 22:635–643. doi:10.1093/humrep/del478 Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD (2004) Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia? Am J Obstet Gynecol 190:1224–1229. doi:10.1016/j.ajog.2003.11.016 Shapley M, Jordan K, Croft PR (2004) An epidemiological survey of symptoms of menstrual loss in the community. Br J Gen Pract 54:359–363 Harlow SD, Campbell OM (2004) Epidemiology of menstrual disorders in developing countries: a systematic review. BJOG 111:6–16. doi:10.1046/j.1471-0528.2003.00012.x Santos IS, Minten GC, Valle NC et al (2011) Menstrual bleeding patterns: a community-based cross-sectional study among women aged 18–45 years in Southern Brazil. BMC Womens Health 11:26. doi:10.1186/1472-6874-11-26 Matteson KA, Boardman LA, Munro MG, Clark MA (2009) Abnormal uterine bleeding: a review of patient-based outcome measures. Fertil Steril 92:205–216. doi:10.1016/j.fertnstert.2008.04.023 Shapley M, Jordan K, Croft PR (2002) Why women consult with increased vaginal bleeding: a case control study. Br J Gen Pract 52:108–113 Shankar M, Chi C, Kadir RA (2008) Review of quality of life: menorrhagia in women with or without inherited bleeding disorders. Haemophilia 14:15–20. doi:10.1111/j.1365-2516.2007.01586.x National Collaborating Centre for Women’s and Children’s Health/National Institute for Health and Clinical Excellence (2007) Heavy menstrual bleeding. NICE clinical guideline 44, RCOG Press, London, UK. Available at: http://www.nice.org.uk/nicemedia/pdf/CG44FullGuideline.pdf Duckitt K, Collins S (2012) Menorrhagia. Clin Evid (Online). 18 Jan 2012. pii: 0805 Critchley HO, Maybin JA (2011) Molecular and cellular causes of abnormal uterine bleeding of endometrial origin. Semin Reprod Med 29:400–409. doi:10.1055/s-0031-1287664 Nelson AL, Teal SB (2007) Medical therapies for chronic menorrhagia. Obstet Gynecol Surv 62:272–281. doi:10.1097/01.ogx.0000259228.70277.6f Drife JO (2011) Oral contraceptives and heavy periods (editorial). Obstet Gynecol 117:773–774. doi:10.1097/AOG.0b013e318212b333 Clarke J (2010) Treatment of heavy menstrual bleeding (editorial). BMJ 341:c3771. doi:10.1136/bmj.c3771 Lukes AS, Kouides PA, Moore KA (2011) Tranexamic acid: a novel oral formulation for the treatment of heavy menstrual bleeding. Womens Health (Lond Engl) 7:151–158. doi:10.2217/whe.11.9 Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS (2011) Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol 117:777–787. doi:10.1097/AOG.0b013e3182118ac3 Alexander NJ, Baker E, Kaptein M, Karck U, Miller L, Zampaglione E (2004) Why consider vaginal drug administration? Fertil Steril 82:1–12. doi:10.1016/j.fertnstert.2004.01.025 Abu Hashim H, Alsherbini W, Bazeed M (2012) Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception 85:246–252. doi:10.1016/j.contraception.2011.07.012 Luisi S, Razzi S, Lazzeri L, Bocchi C, Severi FM, Petraglia F (2009) Efficacy of vaginal danazol treatment in women with menorrhagia during fertile age. Fertil Steril 92:1351–1354. doi:10.1016/j.fertnstert.2008.08.017 Jabbour HN, Sales KJ, Smith OP, Battersby S, Boddy SC (2006) Prostaglandin receptors are mediators of vascular function in endometrial pathologies. Mol Cell Endocrinol 252:191–200. doi:10.1016/j.mce.2006.03.025 Endrikat J, Vilos G, Muysers C, Fortier M, Solomayer E, Lukkari-Lax E (2012) The levonorgestrel-releasing intrauterine system provides a reliable, long-term treatment option for women with idiopathic menorrhagia. Arch Gynecol Obstet 285:117–121. doi:10.1007/s00404-011-1902-1 Kaunitz AM, Inki P (2012) The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review. Drugs 72:193–215. doi:10.2165/11598960-000000000-00000 Kaunitz AM, Meredith S, Inki P, Kubba A, Sanchez-Ramos L (2009) Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol 113:1104–1116. doi:10.1097/AOG.0b013e3181a1d3ce Bahamondes MV, de Lima Y, Teich V, Bahamondes L, Monteiro I (2012) Resources and procedures in the treatment of heavy menstrual bleeding with the levonorgestrel-releasing intrauterine system (LNG-IUS) or hysterectomy in Brazil. Contraception. doi:10.1016/j.contraception.2011.12.005 Matteson KA, Anderson BL, Pinto SB, Lopes V, Schulkin J, Clark MA (2011) Practice patterns and attitudes about treating abnormal uterine bleeding: a national survey of obstetricians and gynecologists. Am J Obstet Gynecol 205:321.e1–8. doi:10.1016/j.ajog.2011.05.016 Farquhar C, Brown J (2009) Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database Syst Rev (4):CD000154. doi:10.1002/14651858.CD000154 Fraser IS, McCarron G (1991) Randomized trial of 2 hormonal and 2 prostaglandin- inhibiting agents in women with a complaint of menorrhagia. Aust N Z J of Obstet Gynaecol 31:66–70. doi:10.1111/j.1479-828X.1991.tb02769.x Endrikat J, Shapiro H, Lukkari-Lax E, Kunz M, Schmidt W, Fortier M (2009) A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can 31:340–347 Shabaan MM, Zakherah MS, El-Nashar SA, Sayed GH (2011) Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception 83:48–54. doi:10.1016/j.contraception.2010.06.011 Miller L, Notter KM (2001) Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol 98:771–778 Collaborative Study Group on the Desogestrel containing Progestogen-only Pill (1998) A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Eur J Contracept Reprod Health Care 3:169–178 Lethaby A, Irvine G, Cameron I (2008) Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev (1):CD001016. doi:10.1002/14651858.CD001016.pub2 Fraser IS (1990) Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynaecol 30:353–356. doi:10.1111/j.1479-828X.1990.tb02028.x Kriplani A, Kulshrestha V, Agarwal N, Diwakar S (2006) Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J Obstet Gynaecol 26:673–678. doi:10.1080/01443610600913932 Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkilä A, Walker JJ, Cameron IT (1998) Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 105:592–598. doi:10.1111/j.1471-0528.1998.tb10172.x Lethaby A, Farquhar C, Cooke I (2000) Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev (4):CD000249. doi:10.1002/14651858.CD000249 Lumsden MA, Wedisinghe L (2011) Tranexamic acid therapy for heavy menstrual bleeding. Expert Opin Pharmacother 12:2089–2095. doi:10(1517/14656566),2011,598857 Naoulou B, Tsai MC (2012) Efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding: a systematic review. Acta Obstet Gynecol Scand. doi:10.1111/j.1600-0412.2012.01361.x Moore K, Morin I, Marenco T et al (2012) Pharmacokinetic studies of two novel oral formulations of tranexamic acid therapy for heavy menstrual bleeding. Am J Ther 19:190–198. doi:10.1097/MJT.0b013e318205427a Lukes A, Moore KA, Muse KN et al (2010) Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 116:865–875. doi:10.1097/AOG.0b013e3181f20177 Freeman EW, Lukes A, VaDrie D, Mabey RG, Gersten J, Adomako TL (2011) A dose–response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. Am J Obstet Gynecol 205:319.e1–7. doi:10.1016/j.ajog.2011.05.015 Ahrendt HJ, Makalova D, Parke S, Mellinger U, Mansour D (2009) Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception 80:436–444. doi:10.1016/j.contraception.2009.03.018 Jensen JT (2010) Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest. Expert Opin Pharmacother 11:1147–1157. doi:10.1517/14656561003724713 Palacios S, Wildt L, Parke S, Machlitt A, Römer T, Bitzer J (2010) Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial. Eur J Obstet Gynecol Reprod Biol 149:57–62. doi:10.1016/j.ejogrb.2009.11.001 Whalen KL, Rose R (2011) Estradiol valerate/dienogest: a novel oral contraceptive. Ann Pharmacother 45:1256–1261. doi:10.1345/aph.1Q216 Klipping C, Duijkers I, Parke S, Mellinger U, Serrani M, Junge W (2011) Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs R D 11:159–170. doi:10.2165/11591200-000000000-00000 Borgelt LM, Martell CW (2012) Estradiol valerate/dienogest: a novel combined oral contraceptive. Clin Ther 34:37–55. doi:10.1016/j.clinthera.2011.11.006 Fraser IS, Römer T, Parke S et al (2011) Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing oestradiol valerate and dienogest: a randomised, double-blind phase III trial. Hum Reprod 26:2698–2708. doi:10.1093/humrep/der224 Micks E, Jensen JT (2011) Estradiol valerate and dienogest: a novel four-phasic oral contraceptive pill effective for pregnancy prevention and treatment of heavy menstrual bleeding. Womens Health (Lond Engl) 7:513–524. doi:10.2217/WHE.11.49 Kiley JW, Shulman LP (2011) Estradiol valerate and dienogest: a new approach to oral contraception. Int J Womens Health 3:281–286. doi:10.2147/IJWH.S22645 Fraser IS, Parke S, Mellinger U, Machlitt A, Serrani M, Jensen J (2011) Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomized, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 16:258–269. doi:10.3109/13625187.2011.591456 Fraser IS, Jensen J, Schaefers M, Mellinger U, Parke S, Serrani M (2012) Normalization of blood loss in women with heavy menstrual bleeding treated with an oral contraceptive containing estradiol valerate/dienogest. Contraception 86:96–101. doi:10.1016/j.contraception.2011.11.011 Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, Muysers C, Jensen JT (2010) Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 116:625–632. doi:10.1097/AOG.0b013e3181ec622b Reid PC, Virtanen-Kari S (2005) Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG 112:1121–1125. doi:10.1111/j.1471-0528.2005.00642.x Roumen FJ (2007) The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials. Contraception 75:420–429. doi:10.1016/j.contraception.2007.01.013 Mulders TM, Dieben TO (2001) Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril 75:865–870. doi:10.1016/S0015-0282(01)01689-2 Oddsson K, Leifels-Fischer B, Wiel-Masson D et al (2005) Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. Hum Reprod 20:557–562. doi:10.1093/humrep/deh604 Sabatini R, Cagiano R (2006) Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception 74:220–223. 10.1016/j.contraception.2006.03.022 Janssen CA, Scholten PC, Heintz AP (1995) A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 85:977–982 Zakherah MS, Sayed GH, El-Nashar SA, Shaaban MM (2011) Pictorial blood loss assessment chart in the evaluation of heavy menstrual bleeding: diagnostic accuracy compared to alkaline hematin. Gynecol Obstet Invest 71:281–284. doi:10.1159/000320336 Lopez LM, Grimes DA, Gallo MF, Schulz KF (2010) Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev (3):CD003552. doi:10.1002/14651858.CD003552.pub3 Bahamondes V, Bahamondes L (2012) “This interesting study shows that that both the contraceptive vaginal ring (CVR) and norethisterone (NET…” Evaluation of: [Abu Hashim H et al. Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception 85:246–252; doi:10.1016/j.contraception.2011.07.012]. Faculty of 1000, 07 Dec 2011. F1000.com/13385972#eval14753078 Beaumont H, Augood C, Duckitt K, Lethaby A (2007) Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev (3):CD001017. doi:10.1002/14651858.CD001017.pub2 Conflict of interest We declare that we have no conflict of interest. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Abu Hashim, H. Medical treatment of idiopathic heavy menstrual bleeding. What is new? An evidence based approach. Arch Gynecol Obstet 287, 251–260 (2013). https://doi.org/10.1007/s00404-012-2605-y Received: Accepted: Published: Issue date: DOI: https://doi.org/10.1007/s00404-012-2605-y

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (67)

Cited by (2)

Source provenance

openalex
last seen: 2026-05-14T06:08:44.784461+00:00
License: CC0 · commercial use OK